Cowen Reiterates “$30.00” Price Target for Immunomedics (NASDAQ:IMMU)

Share on StockTwits

Cowen set a $30.00 target price on Immunomedics (NASDAQ:IMMU) in a report released on Tuesday morning, TipRanks reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Other equities analysts also recently issued reports about the stock. BidaskClub downgraded shares of Immunomedics from a hold rating to a sell rating in a report on Wednesday, August 28th. Jefferies Financial Group set a $22.00 price target on shares of Immunomedics and gave the company a buy rating in a research note on Tuesday. Zacks Investment Research upgraded shares of Immunomedics from a sell rating to a hold rating in a research note on Tuesday, July 16th. ValuEngine upgraded shares of Immunomedics from a buy rating to a strong-buy rating in a research note on Thursday, August 1st. Finally, Cantor Fitzgerald started coverage on shares of Immunomedics in a research note on Monday, August 19th. They issued an overweight rating and a $28.00 price target on the stock. Three analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of $28.33.

Shares of NASDAQ:IMMU traded up $0.28 on Tuesday, hitting $16.00. The company had a trading volume of 9,034 shares, compared to its average volume of 1,934,543. Immunomedics has a 1-year low of $11.55 and a 1-year high of $24.99. The stock has a market cap of $3.10 billion, a price-to-earnings ratio of -15.70 and a beta of 2.06. The stock has a 50 day moving average price of $14.19 and a 200 day moving average price of $15.22. The company has a current ratio of 9.93, a quick ratio of 9.93 and a debt-to-equity ratio of 0.06.

Immunomedics (NASDAQ:IMMU) last released its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.09). During the same quarter in the previous year, the business posted ($0.68) EPS. Sell-side analysts anticipate that Immunomedics will post -1.61 earnings per share for the current fiscal year.

In other news, insider Bryan Ball acquired 5,000 shares of the business’s stock in a transaction that occurred on Thursday, June 20th. The stock was acquired at an average price of $13.35 per share, with a total value of $66,750.00. Following the completion of the transaction, the insider now directly owns 5,000 shares of the company’s stock, valued at approximately $66,750. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Avoro Capital Advisors Llc acquired 1,000,000 shares of the business’s stock in a transaction that occurred on Friday, June 28th. The shares were purchased at an average cost of $13.55 per share, with a total value of $13,550,000.00. The disclosure for this purchase can be found here. Insiders purchased 1,405,000 shares of company stock worth $18,916,750 over the last 90 days. 9.40% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Atria Investments LLC bought a new stake in Immunomedics during the second quarter worth about $1,275,000. United Services Automobile Association lifted its holdings in shares of Immunomedics by 135.6% in the second quarter. United Services Automobile Association now owns 317,992 shares of the biopharmaceutical company’s stock worth $4,411,000 after acquiring an additional 183,041 shares during the last quarter. ClariVest Asset Management LLC bought a new position in shares of Immunomedics in the second quarter worth about $2,810,000. Boxer Capital LLC lifted its holdings in shares of Immunomedics by 60.2% in the second quarter. Boxer Capital LLC now owns 6,567,000 shares of the biopharmaceutical company’s stock worth $91,084,000 after acquiring an additional 2,467,000 shares during the last quarter. Finally, Voloridge Investment Management LLC bought a new position in shares of Immunomedics in the second quarter worth about $2,215,000. 88.59% of the stock is owned by institutional investors and hedge funds.

About Immunomedics

Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.

Featured Article: Systematic Risk

Analyst Recommendations for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Analysts’ Upgrades for September, 20th
Analysts’ Upgrades for September, 20th
Investment Analysts’ New Coverage for September, 20th
Investment Analysts’ New Coverage for September, 20th
Stock Analysts’ Downgrades for September, 20th
Stock Analysts’ Downgrades for September, 20th
Analysts’ Price Target Changes for September, 20th
Analysts’ Price Target Changes for September, 20th
Zacks Investment Research Downgrades Valvoline  to Hold
Zacks Investment Research Downgrades Valvoline to Hold
Speedway Motorsports  Rating Increased to Hold at Zacks Investment Research
Speedway Motorsports Rating Increased to Hold at Zacks Investment Research


© 2006-2019 Ticker Report